-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Luye Pharmaceutical Group announced that the clinical trial application of its independently developed innovative preparation-Ropivacaine Hydrochloride Liposome Suspension Injection (LY09606) has been accepted by the Drug Evaluation Center of the National Medical Products Administration and will soon enter the clinical stage .
Ropivacaine is the first pure L-body long-acting amide local anesthetic, with dual effects of anesthesia and analgesia; large doses can produce surgical anesthesia, while small doses can produce sensory block (analgesia) with only limitations Of non-progressive motor nerve block.
Note: The original text has been deleted